EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression

An-Na Bae iD, Mahsa Mortaja iD, YeePui Yeung, Jiao Huang iD, Jong Ho Park iD, Shadmehr Demehri iD

Cancers · 22.06.2025 · 17 (13) · 2087

DOI: 10.3390/cancers17132087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.06.2025. Verfasst von An-Na Bae und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Chronic inflammation is a key driver of cancer. Interleukin 33 (IL-33) has emerged as a crucial factor involved in the pathogenesis of cancer-prone chronic inflammation. IL-33 functions as a cytokine and a nuclear protein to initiate chronic inflammation and cancer. However, small molecules capable of suppressing IL-33 expression to block its cytokine and nuclear functions are underexplored.

Methods

The impact of tropisetron on IL-33 expression and its role in suppressing pancreatitis and pancreatitis-mediated pancreatic cancer were examined.

Results

We demonstrate that tropisetron suppresses IL-33 expression, with high potential to serve as a novel therapeutic strategy for preventing chronic inflammation and its cancer sequela. Through screening 1018 Food and Drug Administration (FDA)-approved drugs, we discovered that tropisetron, a 5-hydroxytryptamine type 3 (5-HT3) antagonist commonly used to prevent and treat nausea and vomiting, effectively blocked IL-33 expression by suppressing IRF3 activation. Tropisetron inhibited pancreatitis and its progression to pancreatic cancer in mice.

Conclusions

Tropisetron is an IL-33 inhibitor and can provide a novel therapeutic strategy to prevent and treat chronic pancreatitis and its associated cancer.

Schlagwörter

Stichwörter der Autor:innen

Interleukin 33cancer preventionchronic inflammationchronic pancreatitispancreatic cancertropisetron

Autor:innen und Institutionen

  • Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
  • Center for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

ORCID-Profile: An-Na Bae, Mahsa Mortaja, Jiao Huang, Jong Ho Park, Shadmehr Demehri

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Research Foundation of Korea
  • Burroughs Wellcome Fund

Zitieren

APA

Bae, A. N., Mortaja, M., Yeung, Y., Huang, J., Park, J. H., & Demehri, S. (2025). Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression. Cancers, 17(13), 2087. https://doi.org/10.3390/cancers17132087

Vancouver

Bae AN, Mortaja M, Yeung Y, Huang J, Park JH, Demehri S. Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression. Cancers. 2025;17(13):2087. doi:10.3390/cancers17132087

BibTeX
@article{Bae2025,
  author = {Bae, An-Na and Mortaja, Mahsa and Yeung, YeePui and Huang, Jiao and Park, Jong Ho and Demehri, Shadmehr},
  title = {Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {13},
  pages = {2087},
  doi = {10.3390/cancers17132087}
}
Kostenlos starten →